US Stock MarketDetailed Quotes

LCTX Lineage Cell Therapeutics

Watchlist
  • 0.580
  • +0.048+8.98%
Close Jan 10 16:00 ET
  • 0.566
  • -0.015-2.50%
Post 19:57 ET
127.84MMarket Cap-5.80P/E (TTM)

Lineage Cell Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Lineage Cell Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 1.361M--
--2024/Q4-- / 1.621M--
Nov 14, 20242024/Q33.779M / 886.570K--
Aug 8, 20242024/Q21.408M / 786.000K--
May 9, 20242024/Q11.444M / 1.360M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 1.361M--
--2024/Q4-- / 1.621M--
Nov 14, 20242024/Q33.779M / 886.570K--
Aug 8, 20242024/Q21.408M / 786.000K--
May 9, 20242024/Q11.444M / 1.360M--

Unlock Free Earnings Estimates

Lineage Cell Therapeutics Earnings Reports

  • Lineage Cell Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 15, 2024 05:22

  • Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    Nov 15, 2024 05:16

  • Lineage Cell Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 9, 2024 04:21

  • Lineage Cell Therapeutics | 8-K: LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    Aug 9, 2024 04:17

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 10, 2025

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data